Subtopic Deep Dive
Antimicrobial Prophylaxis in Febrile Neutropenia
Research Guide
What is Antimicrobial Prophylaxis in Febrile Neutropenia?
Antimicrobial prophylaxis in febrile neutropenia involves administering fluoroquinolones and antifungals to prevent bacterial and fungal infections in neutropenic cancer patients during chemotherapy-induced fever.
Guidelines from IDSA recommend prophylaxis for high-risk patients based on randomized trials showing reduced infection rates (Hughes et al., 2002; 1970 citations). Key studies compare liposomal amphotericin B and voriconazole for empirical antifungal therapy in persistent fever (Walsh et al., 1999; 1196 citations; Walsh et al., 2002; 984 citations). Over 10 major guidelines and trials shape current practices, with Bodey's foundational work linking leukocyte counts to infection risk (Bodey et al., 1966; 2475 citations).
Why It Matters
Prophylaxis reduces mortality from infections in acute leukemia patients undergoing chemotherapy, directly informing IDSA guidelines adopted worldwide (Hughes et al., 2002; Freifeld et al., 2011). Fluoroquinolone use prevents gram-negative bacteremia but raises resistance concerns in hematological malignancy units (Wisplinghoff et al., 2003). Antifungal agents like voriconazole lower breakthrough infections compared to amphotericin B, improving patient outcomes and reducing hospital stays (Walsh et al., 2002; Walsh et al., 1999). These strategies guide antibiotic stewardship in oncology centers treating over 100,000 neutropenic episodes annually.
Key Research Challenges
Antimicrobial Resistance Emergence
Fluoroquinolone prophylaxis increases resistant gram-negative bacteria in neutropenic units (Wisplinghoff et al., 2003). Balancing infection prevention with stewardship remains difficult in high-risk cancer patients. Guidelines recommend risk-stratified approaches to mitigate this (Freifeld et al., 2011).
Optimal Antifungal Selection
Trials show voriconazole matches liposomal amphotericin B efficacy but with less toxicity in persistent fever (Walsh et al., 2002). Choosing agents requires weighing breakthrough infections and cost in resource-limited settings (Walsh et al., 1999). IDSA updates stress evidence-based empirical therapy (Hughes et al., 2002).
Risk Stratification Accuracy
Defining high-risk neutropenia relies on leukocyte thresholds from early studies (Bodey et al., 1966). Modern chemotherapy regimens complicate predictions of febrile episodes (Crawford et al., 2004). Guidelines evolve to incorporate transplantation status and duration (Tomblyn et al., 2009).
Essential Papers
Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia
Gerald P. Bodey, MONICA BUCKLEY, Y. S. SATHE et al. · 1966 · Annals of Internal Medicine · 2.5K citations
Article1 February 1966Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaGERALD P. BODEY, M.D., MONICA BUCKLEY, B.A., Y. S. SATHE, PH.D., EMIL J ...
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
Walter T. Hughes, Donald Armstrong, Gerald P. Bodey et al. · 2002 · Clinical Infectious Diseases · 2.0K citations
This article, prepared by the Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guidelines Panel, updates guidelines established a decade ago by the Infectious Disease Society of ...
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
Marcie Tomblyn, Tom Chiller, Hermann Einsele et al. · 2009 · Biology of Blood and Marrow Transplantation · 1.7K citations
Guidelines for Treatment of Candidiasis
Peter G. Pappas, John Rex, Jack D. Sobel et al. · 2004 · Clinical Infectious Diseases · 1.4K citations
Good evidence to support a recommendation against use Quality of evidence 1 Evidence from у1 properly randomized, controlled trial 2 Evidence from у1 well-designed clinical trial, without randomiza...
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Thomas J. Walsh, Robert W. Finberg, Carola Arndt et al. · 1999 · New England Journal of Medicine · 1.2K citations
Liposomal amphotericin B is as effective as conventional amphotericin B for empirical antifungal therapy in patients with fever and neutropenia, and it is associated with fewer breakthrough fungal ...
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
Thomas J. Walsh, Peter G. Pappas, Drew J. Winston et al. · 2002 · New England Journal of Medicine · 984 citations
Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever.
Chemotherapy‐induced neutropenia
Jeffrey Crawford, David C. Dale, Gary H. Lyman · 2004 · Cancer · 855 citations
Abstract Cytotoxic chemotherapy suppresses the hematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the most serious...
Reading Guide
Foundational Papers
Start with Bodey et al. (1966) for leukocyte-infection relationships (2475 citations), then Hughes et al. (2002) IDSA guidelines (1970 citations) for prophylaxis protocols, followed by Walsh et al. (1999) on liposomal amphotericin B efficacy.
Recent Advances
Study Freifeld et al. (2011) executive summary updating IDSA recommendations (699 citations) and Tomblyn et al. (2009) transplantation guidelines (1727 citations) for prophylaxis in high-risk groups.
Core Methods
Core techniques include randomized trials of empirical antifungals (Walsh et al., 2002), cohort analyses of resistance (Wisplinghoff et al., 2003), and guideline consensus from IDSA panels (Hughes et al., 2002).
How PapersFlow Helps You Research Antimicrobial Prophylaxis in Febrile Neutropenia
Discover & Search
Research Agent uses searchPapers and citationGraph to map IDSA guideline evolution from Hughes et al. (2002) to Freifeld et al. (2011), revealing 1970+ citations linking to prophylaxis trials. exaSearch uncovers resistance data in Wisplinghoff et al. (2003), while findSimilarPapers expands to antifungal comparisons like Walsh et al. (2002).
Analyze & Verify
Analysis Agent applies readPaperContent to extract prophylaxis recommendations from Hughes et al. (2002), then verifyResponse with CoVe checks consistency across Freifeld et al. (2011). runPythonAnalysis computes meta-analysis of infection rates from Bodey et al. (1966) and Walsh et al. (1999) using pandas, with GRADE grading for evidence quality in randomized trials.
Synthesize & Write
Synthesis Agent detects gaps in resistance data post-fluoroquinolone use via contradiction flagging between Wisplinghoff et al. (2003) and guidelines. Writing Agent uses latexEditText and latexSyncCitations to draft guideline summaries citing Walsh et al. (2002), with latexCompile for publication-ready tables and exportMermaid for prophylaxis decision trees.
Use Cases
"Extract and plot infection rates vs leukocyte counts from Bodey 1966 for prophylaxis risk models."
Research Agent → searchPapers('Bodey 1966') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot of rates) → matplotlib figure of quantitative relationships.
"Draft LaTeX review comparing voriconazole vs amphotericin B in neutropenic fever."
Research Agent → citationGraph(Walsh 2002) → Synthesis Agent → gap detection → Writing Agent → latexEditText(draft) → latexSyncCitations(Hughes 2002, Walsh 1999) → latexCompile(PDF review).
"Find code for simulating neutropenia prophylaxis resistance models."
Research Agent → paperExtractUrls(Wisplinghoff 2003) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(adapt simulation code for fluoroquinolone resistance curves).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers on prophylaxis, chaining searchPapers → citationGraph → GRADE grading for IDSA guideline synthesis (Hughes et al., 2002). DeepScan applies 7-step analysis with CoVe verification to Walsh et al. (2002) trial data, checkpointing efficacy vs toxicity. Theorizer generates stewardship models from resistance patterns in Wisplinghoff et al. (2003) and Bodey et al. (1966).
Frequently Asked Questions
What is antimicrobial prophylaxis in febrile neutropenia?
It is preventive use of fluoroquinolones and antifungals in high-risk neutropenic cancer patients to reduce infection rates during chemotherapy-induced fever (Hughes et al., 2002).
What are key methods in prophylaxis trials?
Randomized controlled trials compare empirical antifungals like voriconazole vs liposomal amphotericin B for persistent fever, assessing breakthrough infections and toxicity (Walsh et al., 2002; Walsh et al., 1999).
What are seminal papers?
Bodey et al. (1966; 2475 citations) quantify leukocyte-infection links; Hughes et al. (2002; 1970 citations) provide IDSA guidelines on agents.
What open problems exist?
Emerging resistance to fluoroquinolones and optimal risk stratification beyond leukocyte counts challenge guidelines (Wisplinghoff et al., 2003; Freifeld et al., 2011).
Research Neutropenia and Cancer Infections with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antimicrobial Prophylaxis in Febrile Neutropenia with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Neutropenia and Cancer Infections Research Guide